go-v.orgdoi

A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes

Camila Motta Venchiarutti Moniz, Rachel P. Riechelmann, Suilane Coelho Ribeiro Oliveira, Giovanni Mendonca Bariani, Thomás Giollo Rivelli, Cintia Ortega, Allan Andresson Lima Pereira, Sibele Inácio Meireles, Rejane Carolina de Oliveira Franco, Andrè Chen, Renata Colombo Bonadio, Caio Sérgio Rizkallah Nahas, Jorge Sabbaga, Renata A. Coudry, Maria Ignez Braghiroli, Paulo M. Hoff · Journal of Cancer · 2021

  • DOI 10.7150/jca.57678
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2021

Abstract

Background: Although Chemoradiation (CRT) is the curative treatment for SCCAC, many patients present primary resistance.Since it is a rare tumor, response predictors remain unknown.Methods: We performed a prospective cohort study to evaluate biomarkers associated with CRT response, progression-free survival (PFS), and overall survival (OS).The primary endpoint was response at 6 months (m).Tumor DNA and HPV were analyzed by next-generation sequencing, while KI-67 and PD-L1 by immunohistochemistry in tumor tissue.Results: Seventy-eight patients were recruited between October/2011 and December/2015, and 75 were response evaluable.The median age was 57 years, 65% (n=49) were stage III and 12% (n=9) were HIV positive (HIV+).At 6m, 62.7% (n=47) presented CR.On multivariate analyses, stage II patients were 4.7 more likely to achieve response than stage III (OR, 4.70; 95%CI, 1.36-16.30;p=0.015).HIV+ was associated with a worse response (OR, 5.72; 95%CI, 2.5-13.0;p<0.001).5-year PFS and OS rates were 63.3% and 76.4%, respectively, with a median follow up of 66m.On multivariate analyses, older age (HR 1.06, p=0.022, 95%IC 1.01-1.11)and absence of CR at 6m (HR 3.36, p=0.007, 95%IC 1.39-8.09)were associated with inferior OS.The 5-year OS rate was 62.5% in HIV+ group compared to 78% among HIVpts, although this difference was not statistically significant (p=0.4).PIK3CA, MET and TP53 mutations, HPV, Ki-67 expression, and PD-L1 expression, were not associated with PFS and OS.Conclusions: Clinical stage III and HIV+ were associated with worse response to CRT at 6m.The absence of CR was the main factor associated with poor 5-year OS.

Open the resolved locator · 10.7150/jca.57678

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:33 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v12p7018.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.